Hypergravity enhances the therapeutic effect of dexamethasone in allergic asthma and rhinitis animal model

Jang, Tae Young; Jung, Ah-Yeoun; Kwon, Soonjo; Kim, Young Hyo

doi:10.1371/journal.pone.0197594

Cited by 10 publications

(7 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dexamethasone treatment did not reduce the levels of IgE and IgG2a, suggesting that the sakuranetin treatment was more effective for the sensitization compared to DX. Similar data was demonstrated by Jang et al in 2018, who showed that DX treatment did not reduce the levels of the OVA-specific IgE antibody [36]. Sakuranetin treatment also reduced the thymus and spleen hypertrophy, suggesting that it suppresses the immune response.…”

Section: Discussionsupporting

confidence: 84%

Inhibition of MAPK and STAT3-SOCS3 by Sakuranetin Attenuated Chronic Allergic Airway Inflammation in Mice

Santana

Silva

Grecco

et al. 2019

Mediators of Inflammation

View full text Add to dashboard Cite

Asthma allergic disease is caused by airway chronic inflammation. Some intracellular signaling pathways, such as MAPK and STAT3-SOCS3, are involved in the control of airway inflammation in asthma. The flavonoid sakuranetin demonstrated an anti-inflammatory effect in different asthma models. Our aim was to clarify how sakuranetin treatment affects MAPK and STAT3-SOCS3 pathways in a murine experimental asthma model. Mice were submitted to an asthma ovalbumin-induction protocol and were treated with vehicle, sakuranetin, or dexamethasone. We assayed the inflammatory profile, mucus production, and serum antibody, STAT3-SOCS3, and MAPK levels in the lungs. Morphological alterations were also evaluated in the liver. LPS-stimulated RAW 264.7 cells were used to evaluate the effects of sakuranetin on nitric oxide (NO) and cytokine production. In vivo, sakuranetin treatment reduced serum IgE levels, lung inflammation (eosinophils, neutrophils, and Th2/Th17 cytokines), and respiratory epithelial mucus production in ovalbumin-sensitized animals. Considering possible mechanisms, sakuranetin inhibits the activation of ERK1/2, JNK, p38, and STAT3 in the lungs. No alterations were found in the liver for treated animals. Sakuranetin did not modify in vitro cell viability in RAW 264.7 and reduced NO release and gene expression of IL-1β and IL-6 induced by LPS in these cells. In conclusion, our data showed that the inhibitory effects of sakuranetin on eosinophilic lung inflammation can be due to the inhibition of Th2 and Th17 cytokines and the inhibition of MAPK and STAT3 pathways, reinforcing the idea that sakuranetin can be considered a relevant candidate for the treatment of inflammatory allergic airway disease.

show abstract

Section: Discussionsupporting

confidence: 84%

Inhibition of MAPK and STAT3-SOCS3 by Sakuranetin Attenuated Chronic Allergic Airway Inflammation in Mice

Santana

Silva

Grecco

et al. 2019

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…At present, the role of inhaled corticosteroids in asthmatic airway remodeling has received increasing attention. 12 Studies have found that glucocorticoid dexamethasone can inhibit ASMC proliferation. 13 Some scholars have found that dexamethasone can alleviate the symptoms of allergic asthma rats.…”

Section: Discussionmentioning

confidence: 99%

Effects of Recombinant Irisin on Body Mass Index, Serum Insulin, Luteinizing Hormone and Testosterone Levels in Obese Female BALB/c Mice

Majeed¹,

Shafi²,

Moin³

et al. 2019

J Coll Physicians Surg Pak

View full text Add to dashboard Cite

after approval by the Committee on Animal Research and Ethics. Thirty healthy male SPF Sprague-Dawley rats were randomly divided into the control group, the model group, and the dexamethasone group by random number table, with 10 rats in each group. On the 1st and 8th day, 1 mL of ovalbumin (OVA) (1 mg) + Al (OH) 3 (100 mg) saline solution was intraperitoneally injected for sensitisation, and the rats were placed in a semi-closed container.

show abstract

“…Although GC therapy is commonly applied in allergic airway inflammation, such as asthma and allergic rhinitis, some limitations of GCs still exist; for example, the current guidelines on dosing vary between countries, and side effects should not be ignored [19]. To maximize therapeutic effects while minimizing potential side effects, combination therapies with GCs have been explored, including other drugs [14], supplementary measures such as hypergravity [20] and nutrients [15]. Among these options, dietary nutrients might be the most convenient and safe.…”

Section: Discussionmentioning

confidence: 99%

Supplementation with Tetrahydrocurcumin Enhances the Therapeutic Effects of Dexamethasone in a Murine Model of Allergic Asthma

Chen

Qin

et al. 2020

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Tetrahydrocurcumin (THC) is the major active metabolite of curcumin, which is a dietary factor derived from Curcuma species. Our previous study demonstrated a significant beneficial effect of THC in mice with allergic asthma. Glucocorticosteroids (GCs) are commonly used drugs in asthma. Whether THC supplementation could promote the beneficial effects of GC therapy on asthma has not yet been reported. The current study aimed to investigate the combined efficacy of GC and THC treatment in a mouse model of allergic asthma. Methods: BALB/c mice were randomly divided into 5 groups: the control group, ovalbumin (OVA)-induced group, and OVA-induced mice treated with dietary THC only, intraperitoneal injection of dexamethasone (DEX) only, or THC combined with DEX. The nasal symptoms, histopathological alterations of lung tissues, lung cytokine production, and Th cell subsets were assessed. Results: THC or DEX had beneficial effects on nasal symptoms and pathological lung changes, and the therapeutic effects between THC and DEX treatment were comparable. Importantly, compared to the monotherapy groups (THC or DEX only), the combination of THC and DEX showed a significantly reduced nasal rubbing frequency, lower mucus hyperproduction, lower Th2 and Th17 cell numbers as well as lower related cytokine levels (IL-4, IL-5, and IL-17A). Conclusions: Supplementation with THC can enhance the therapeutic effects of DEX to alleviate airway symptoms, lung inflammation, and the Th2 response. Our findings suggest that dietary administration of THC could act as an add-on therapy for asthma treated with GCs.

show abstract

Hypergravity enhances the therapeutic effect of dexamethasone in allergic asthma and rhinitis animal model

Cited by 10 publications

References 27 publications

Inhibition of MAPK and STAT3-SOCS3 by Sakuranetin Attenuated Chronic Allergic Airway Inflammation in Mice

Inhibition of MAPK and STAT3-SOCS3 by Sakuranetin Attenuated Chronic Allergic Airway Inflammation in Mice

Effects of Recombinant Irisin on Body Mass Index, Serum Insulin, Luteinizing Hormone and Testosterone Levels in Obese Female BALB/c Mice

Supplementation with Tetrahydrocurcumin Enhances the Therapeutic Effects of Dexamethasone in a Murine Model of Allergic Asthma

Contact Info

Product

Resources

About